Zhitong Finance App News, Wantai Biotech (603392.SH) issued an announcement. Recently, Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, received the administrative license “Notice of Acceptance” from the State Drug Administration, and the clinical trial application for the “recombinant trivalent rotavirus subunit vaccine (Escherichia coli)” declared by the company has been accepted.

Zhitong Finance App News, Wantai Biotech (603392.SH) issued an announcement. Recently, Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, received the administrative license “Notice of Acceptance” from the State Drug Administration, and the clinical trial application for the “recombinant trivalent rotavirus subunit vaccine (Escherichia coli)” declared by the company has been accepted.